Monitoring Plasmodium vivax chloroquine sensitivity along China-Myanmar border of Yunnan Province, China during 2008-2013

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Liu, Hui ^a   Yang, Heng Lin ^a   Tang, Lin Hua ^b   Li, Xing Liang ^a   Huang, Fang ^b   Wang, Jia Zhi ^c   Li, Chun Fu ^a   Wang, Heng Ye ^a   Nie, Ren Hua ^a   Guo, Xiang Rui ^d   Lin, Ying Xue ^d   Li, Mei ^b   Xu, Jian Wei ^a  

^a Yunnan Institute of Parasitic Diseases   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Tengchong County Center for Disease Control and Prevention   (China)

^d Yangjiang County Center for Disease Control and Prevention   (China)

Author keywords

China Myanmar border; Chloroquine; Plasmodium vivax; Resistance

Indexed keywords

CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; PRIMAQUINE; ANTIMALARIAL AGENT;

ADOLESCENT; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; BODY WEIGHT; CHILD; CHINA; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYANMAR; PARASITE CLEARANCE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; REINFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; INFANT; MALARIA, VIVAX; MIDDLE AGED; PARASITOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHINA; CHLOROQUINE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALARIA, VIVAX; MALE; MIDDLE AGED; PLASMODIUM VIVAX; YOUNG ADULT;

EID: 84907909952     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-364     Document Type: Article

References (30)

1. WHO, World Malaria Report 2011 Geneva: World Health Organization 2011
2. Ministry of Health, People's Republic of China, From Malaria Control to Elimination: a Revised National Malaria Strategy 2010-2015 Beijing: Ministry of Health 2009 2 4
3. Ministry of Health, People's Republic of China, Malaria Elimination Action Plan 2010-2020(in Chinese) Beijing: Ministry of Health 2010 1 2
4. The changing epidemiology of malaria elimination: new strategies for new challenges. Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RGA, Lancet 2013 382 900 911 10.1016/S0140-6736(13)60310-4 23594387
5. Drug-resistant malaria: molecular mechanisms and implications for public health. Petersen I, Eastman R, Lanzer M, FEBS Lett 2011 585 1551 1562 10.1016/j.febslet.2011.04.042 21530510
6. Challenges and prospects for malaria elimination in the Greater Mekong. Cui L, Yan G, Sattabongkotc J, Chen D, Cao Y, Fan Q, Parkera D, Sirichaisinthopg J, Su XZ, Yang H, Yang Z, Wang B, Zhou G, Acta Trop 2012 121 240 245 10.1016/j.actatropica.2011.04.006 21515238
7. Vivax malaria: neglected and not benign. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM, Am J Trop Med Hyg 2007 77 79 87 18165478
8. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Price RN, Douglas NM, Anstey NM, Curr Opin Infect Dis 2009 22 430 435 10.1097/QCO.0b013e32832f14c1 19571748
9. Plasmodium vivax resistance to chloroquine? Rieckmann KH, Davis DR, Hutton DC, Lancet 1989 2 1183 1184 2572903
10. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, Lindegardh N, Singhasivanon P, White NJ, Nosten F, Clin Infect Dis 2011 53 977 984 10.1093/cid/cir631 22002979
11. World Health Organization, Method for Surveillance of Antimalarial Drug Efficacy Geneva: World Health Organization 2009 12 82 http://www.who.int/malaria/resistance
12. Bureau for Disease control and prevention, Ministry of Health, People's Republic of China, Malaria Control Manual (in Chinese) Beijing: People's Health Publishing Company 2007 33 42
13. Monitoring Plasmodium falciparum chloroquine resistance in Yunnan Province, China, 1981-2006. Yang HL, Yang Y, Yang PF, Acta Trop 2008 108 44 49 10.1016/j.actatropica.2008.08.010 18822265
14. Studies on identification of circumsporozoite protein genotyping of Plasmodium vivax] (in Chinese). Huang T, Wang X, Li X, Huang Y, Zeng C, Zhang S, Fu W, Zhang Z, Zhang G, Chin J Parasitol Parasit Dis 2000 18 272 276
15. Organization WH, Guidelines for the Treatment of Malaria Geneva: World Health Organization 2006 1 66
16. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Stepniewska K, White NJ, Malar J 2006 5 127 10.1186/1475-2875-5-127 17187673
17. The analysis of clinical characteristics for 47 patient cases of chloroquine-resistant Plasmodium vivax (in Chinese). Wei D, Li GL, Huang YS, Dai CF, Chen GL, Southwestern Defence Med 2000 10 86 87
18. The clinical study on Plasmodium vivax chloroquine sensitivity (in Chinese). Yang XM, Yang MQ, Huang JW, Zhao FX, Chinese J Parasitic Dis Control 1996 9 226 227
19. Evaluation of the sensitivity of vivax malaria to chloroquine in the City of Laza, Myanmar (in Chinese). Liang GL, Su XD, Wang J, Zhang ZX, J Pathogen Biol 2010 5 362 372
20. In vitro sensitivity test of Plasmodium vivax to chloroquine in center part of China (in Chinese). Lu F, Gao Q, Xia H, Tao Z, Cao J, Gu Y, Zhou H, Jin X, Udomsangpetch R, Sattabongkot J, Chin J Schisto Control 2006 18 265 267
21. Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Myat Phone K, Myint O, Myint L, Thaw Z, Kyin Hla A, Nwe Nwe Y, Trans R Soc Trop Med Hyg 1993 87 687 10.1016/0035-9203(93)90294-Z 8296378
22. Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Marlar T, Myat Phone K, Aye Yu S, Khaing Khaing G, Ma S, Myint O, Trans R Soc Trop Med Hyg 1995 89 307 308 10.1016/0035-9203(95)90556-1 7660445
23. A new high-throughput method for simultaneous detection of drug resistance associated mutations in Plasmodium vivax dhfr, dhps and mdr1 genes. Barnadas C, Kent K, Timinao1 L, Iga1 J, Gray L, Siba1 P, Mueller I, Thomas P, Zimmerman P, Malar J 2011 10 282 10.1186/1475-2875-10-282 21943242
24. Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Guthmann JP, Pittet A, Lesage A, Trop Med Int Health 2008 13 91 98 10.1111/j.1365-3156.2007.01978.x 18291007
25. Chloroquine resistance in Plasmodium vivax. Baird JK, Antimicrob Agents Chemother 2004 48 4075 4083 10.1128/AAC.48.11.4075-4083.2004 15504824
26. Chloroquine-resistant Plasmodium vivax in the Republic of Korea. Lee KS, Kim TH, Kim ES, Am J Trop Med Hyg 2009 80 215 217 19190216
27. Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey. Kurcer MA, Simsek Z, Zeyrek FY, Ann Trop Med Parasitol 2004 98 447 451 10.1179/000349804225021343 15257793
28. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Teka H, Petros B, Yamuah L, Malar J 2008 7 220 10.1186/1475-2875-7-220 18959774
29. Chloroquine resistant Plasmodium vivax, Brazilian Amazon. Santana Filho FS, Arcanjo AR, Chehuan YM, Emerg Infect Dis 2007 13 1125 1126 10.3201/eid1307.061386 18214203
30. Artemisinin combination therapy for vivax malaria. Douglas N, Nicholas N, Angus B, Nosten F, Price R, Lancet Infect Dis 2010 10 405 416 10.1016/S1473-3099(10)70079-7 20510281